Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Fabio P.S. Santos, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Charles A. Koller, MD, Miloslav Beran, MD, PhD, Gautam Borthakur, MD, Carlos Bueso-Ramos, MD, PhD, Michael Keating, MB, BS, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2008) 112 (11): 925.

https://doi.org/10.1182/blood.V112.11.925.925

Published: 2008

Journal Articles

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Miloslav Beran, MD PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD PhD, Gautam Borthakur, MD, Michael Andreeff, MD PhD, Steve Kornblau, MD, Susan O’Brien, MD, Khanh Vu, MD, Monica Kwari, RN, Jennie Bretz, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4324.

https://doi.org/10.1182/blood.V110.11.4324.4324

Published: 2007

Journal Articles

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Charles Koller, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Susan O’Brien, MD

Blood (2007) 110 (11): 2824.

https://doi.org/10.1182/blood.V110.11.2824.2824

Published: 2007

Journal Articles

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Jeffrey L. Jorgensen, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Charles Asa Koller, MD, Miloslav Beran, MD, PhD, Steven M. Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Dan Jones, MD, PhD, Susan O’Brien, MD

Blood (2006) 108 (11): 1861.

https://doi.org/10.1182/blood.V108.11.1861.1861

Published: 2006

Journal Articles

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Stefan Faderl, MD, Alessandra Ferrajoli, MD, Farhad Ravandi-Kashani, MD, Srdan Verstovsek, MD, PhD, William G. Wierda, MD, PhD, Gautam Borthakur, MD, Deborah Thomas, MD, Jorge Cortes, MD, Steven M. Kornblau, MD, Zeev Estrov, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, DVM, Francis Giles, MD, Xuelin Huang, PhD, Monica Kwari, RN, Hagop M. Kantarjian, MD

Blood (2006) 108 (11): 159.

https://doi.org/10.1182/blood.V108.11.159.159

Published: 2006

Journal Articles

Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome.

Elias Jabbour, MD, Hagop Kantarjian, MD, Miloslav Beran, MD, PhD, DVM, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Sherry Pierce, RN, BSN, BA, Jianqin Shan, PhD, William Plunkett, MD, PhD, Michael Keating, MD, Elihu Estey, MD

Blood (2005) 106 (11): 2529.

https://doi.org/10.1182/blood.V106.11.2529.2529

Published: 2005

Journal Articles

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, Steven Kornblau, MD, PhD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Laurie Letvak, MD, August Salvado, MD, Richard Champlin, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 1830.

https://doi.org/10.1182/blood.V106.11.1830.1830

Published: 2005

Journal Articles

Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Jorge Cortes, MD, Susan O’Brien, MD, Stefan Faderl, MD, Farhad Ravandi, MD, Gullermo Garcia-Manero, MD, Francis Giles, MD, Miloslav Beran, MD, PhD, Charles Koller, MD, William Wierda, MD, PhD, Srdan Verstovsek, MD, PhD, Alessandra Ferrajoli, MD, PhD, Steven Kornblau, MD, PhD, Michael Keating, MD, Michael Andreeff, MD, PhD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 1831.

https://doi.org/10.1182/blood.V106.11.1831.1831

Published: 2005

Journal Articles

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Stefan Faderl, MD, Deborah A. Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Miloslav Beran, MD, PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, MD, Michael Andreeff, MD, PhD, Steve Kornblau, MD, Khanh Vu, MD, Rita Jarmon, R.N., Hagop M. Kantarjian, MD

Blood (2005) 106 (11): 1840.

https://doi.org/10.1182/blood.V106.11.1840.1840

Published: 2005

Journal Articles

Prolonged Administration of Arsenic Trioxide (Trisenox®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.

Miloslav Beran, MD, PhD, Srdan Verstovsek, MD, Steven M. Kornblau, MD, Elihu H. Estey, MD, Francis Giles, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD

Blood (2004) 104 (11): 4731.

https://doi.org/10.1182/blood.V104.11.4731.4731

Published: 2004

Journal Articles

Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes.

Hesham M. Amin, MD, MSc, Sherry A. Pierce, RN, Hagop M. Kantarjian, MD, Michael J. Keating, MD, Emil J. Freireich, MD, Charles A. Koller, MD, Miloslav Beran, MD, PhD, Maher Albitar, MD, Susan M. O’Brien, MD, Elihu H. Estey, MD

Blood (2004) 104 (11): 2371.

https://doi.org/10.1182/blood.V104.11.2371.2371

Published: 2004

Journal Articles

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Stefan Faderl, MD, Jorge Cortes, MD, Susan O’Brien, MD, Francis Giles, MD, Guillermo Garcia, MD, Steven Kornblau, MD, Michael Andreeff, MD, PhD, Miloslav Beran, MD, PhD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Laurie Letvak, MD, August Salvado, MD, Richard Champlin, MD, Hagop Kantarjian, MD

Blood (2004) 104 (11): 2738.

https://doi.org/10.1182/blood.V104.11.2738.2738

Published: 2004

Journal Articles

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Stefan Faderl, MD, Varsha Gandhi, PhD, Srdan Verstovsek, MD, PhD, Jorge Cortes, MD, Farhad Ravandi-Kashani, MD, Miloslav Beran, MD, PhD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Susan O’Brien, MD, Alessandra Ferrajoli, MD, Zeev Estrov, MD, Monica Kwari, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD

Blood (2004) 104 (11): 875.

https://doi.org/10.1182/blood.V104.11.875.875

Published: 2004

Journal Articles

Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.

Deborah A. Thomas, MD, Jorge Cortes, MD, Stefan Faderl, MD, Susan O’Brien, MD, Miloslav Beran, MD, PhD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Anas Younes, MD, Luis Fayad, MD, William Wierda, MD, PhD, Sherry Pierce, RN, Francis J. Giles, MD, Hagop Kantarjian, MD

Blood (2004) 104 (11): 3297.

https://doi.org/10.1182/blood.V104.11.3297.3297

Published: 2004

NARROW

Acute Erythroleukemia: An Analysis of 108 Patients Treated with Cytarabine-Containing Regimens at the M.D. Anderson Cancer Center.

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Update of the Modified Hyper-CVAD Regimen with or without Rituximab as Frontline Therapy of Adults with Acute Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL).

Outcome after Detection of Minimal Residual Disease during Treatment with the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL).

Clofarabine Plus Anthracycline Combinations in Acute Myeloid Leukemia (AML) Salvage.

Long-Term Follow-Up Results of the Combination of Topotecan and Cytarabine and Other Intensive Chemotherapy Regimens in Myelodysplastic Syndrome.

Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL).

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Prolonged Administration of Arsenic Trioxide (Trisenox®) for Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) at MD Anderson Cancer Center: A Phase II Study.

Increased Bone Marrow Erythroid Precursors Is Associated with Shorter Survival in Low-Grade Myelodysplastic Syndromes.

Update of the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL).

Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).

Outcome with the Hyper-CVAD and Rituximab Regimen in Burkitt (BL) and Burkitt-Like (BLL) Leukemia/Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only